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Abstract 
Background: Between 2000 and 2013, spending on medicines in Korea increased by  275.3%. In 
order to curb this trend, several pricing policies and measures were introduced. Objectives: This 
study reviews these policies and their implications. Methods: Review of pricing regulations as well as 
a literature review. Results: New medicines must now undergo both a reimbursement assessment 
and price negotiations. The reimbursement of new medicines is based on their cost-effectiveness. 
The prices of new medicines are subsequently fixed through negotiations between the payer, the 
National Health Insurance Service, and the relevant manufacturer. Generic drugs are automatically 
priced via a new standard methodology. Re-pricing mechanisms were complicated and now 
redundant. Conclusions: Simple and efficient measures rather than complex and inefficient 
measures are needed to maintain the value for money principle for new medicines as well as achieve 
financial efficiency through price competition among multiple s sourced drugs, building on the 
experiences in other countries. 
 
Key points for decision makers 
x Price regulations are necessary for the sustainability of health insurance plans in Korea. Various 
pricing mechanisms are being applied in accordance with the types of medicines.  
x The positive listing based on cost-effectiveness appraisals and price negotiations has been 
implemented for new medicines since 2007. Repricing mechanisms including price-volume 
agreement, price cuts and delisting are now in place.  
x Simple and efficient measures rather than complex and measures which can be problematic are 
needed to maintain the value for money principles as well as to achieve financial efficiency. This 
include pricing competition among generic drugs as well as additional initiatives to enhance their 
use 
 
Introduction and Aims 
Drug expenditure increased in Korea by 275.3% between2000 and 2013, when several policies were 
implemented In order to curb this increasing trend in pharmaceutical spending. This included th 
separation of dispensing from prescribing,  
 
Other initiatives in recent years included the Drug Expenditure Rationalization Plan (DERP), 
announced in December 29, 2006, and coming into effect in 2007. The two main pillars of the DERP 
were the positive list system (PLS), developed via cost-effectiveness appraisals, and the price 
negotiation procedure between the payer, the National Health Insurance Service (NHIS), and 
pharmaceutical manufacturers [2]. 
 
 
 
The PLS is characterized as a selective listing of medicines with the aim of obtaining value for money 
in drug expenditure. Consequently, it emphasizes the importance of cost-effectiveness in addition to 
clinical effectiveness. The second pillar, price negotiation, is a new procedure in drug pricing that is 
independently executed from listing decisions. 
 
In April 2012, a new drug pricing policy for off-patent drugs was introduced. This policy set the 
reimbursement price for outpatient drugs in order to strengthen market competition. The effect of 
these policies in terms of price competition among outpatient drugs is still questionable [3]. However, 
drug expenditure reduced in 2012 compared to 2011 although slightly increased in 2013 albeit at a 
lower rate than before as shown in Figure 1. Existing drug pricing policies though have now become 
complicated because numerous measures are now being applied.  
 
Consequently, the aim of this study is to appraise current pricing policies for medicines in South 
Korea through an examination of pricing regulations and a literature review. This is not a systematic 
review. However, the opinions and the comments made are based on the considerable knowledge of 
the co-authors regarding the situation in South Korea combined with publications in this area, 
including publications of the co-authors. It is hoped these comments will stimulate debates in this 
important area to among relevant authorities in South Korea to improve the current situation, 
benefitting all key stakeholders in the future. 
 
Korean Pharmaceutical Benefit Scheme 
The Korean National Health Insurance (NHI) was introduced in 1977 and achieved almost universal 
health coverage by 1989 [4]. It is a mandatory insurance in which 97% of the total population is 
enrolled. While population coverage is close to 100%, service coverage as of 2010 was only 58.7%, 
which is lower than the OECD average (73.1%). However, the benefit coverage for pharmaceuticals is 
ZKLFKLVVLPLODUWR2(&'FRXQWULHV¶ average of 60.3%[5].  
 
In 2006, expenditure on medicines in South Korea was 29.4% of total healthcare expenditure; 
consequently,  a significant proportion of overall expenditure justifying increasing scrutiny. After 2007, 
numerous policy reforms regarding medicine prices were instigated, with spending on pharmaceutical 
expenditure decreasing to 26.1% of total healthcare expenditure in 2013. However, this is still high 
compared to the average of OECD countries at 16.9% [6], necessitating additional measures for the 
future sustainability of the Korean healthcare system. 
 
As of January 1, 2014, 15,734 medicines have been registered in South Korea under the NHI. Drug 
spending in 2013, via claims data, was Korean Won (KRW) 13.2 trillion (USD 11,744 million, 
USD/KRW = 1,124 as of July 2016) comprising, as mentioned, 26.1% of the total health expenditure. 
Expenditure for outpatient prescriptions was approximately 68.7% of the total pharmaceutical 
expenditure, with the remaining medicines used in hospitals [1]. There are several types of medicines 
available in Korea including new medicines, generic medicines, and line extensions. These will now 
be described in more detail, with comparisons with other countries where pertinent including generic 
prices in Europe. The price of medicines is regulated by the government under the NHI.. The costs of 
prescribed drugs are compensated by the NHIS, with patient co-payment for prescribed drugs 
approximately 30%. The price regulation for medicines is currently managed by the Health Insurance 
Review and Assessment (HIRA) agency and the NHIS, and final approvals are made by the Ministry 
of Health and Welfare (MOHW). 
 
Drug pricing in South Korea 
Different measures regarding drug pricing in South Korea are currently applicable depending on the 
types of medicine. Table 1 shows an overview of the pricing mechanisms for each type of medicine. 
 
 
 
New drug pricing 
New drugs (NMEs) now have to undergo two independent procedures for their listing and pricing 
>)LJXUH@$FFRUGLQJWRWKH'(53WKHVHSURFHGXUHVDUH+,5$¶s decision-making on reimbursements 
DQG1+,6¶SULFLQJQHJRWLDWLRQV)LUVt, HIRA evaluates the potential reimbursement of new drugs 
considering several factors. These include cost-effectiveness, clinical usefulness and budget impact. 
Until 2007, almost all medicines that received market approval from the Ministry of Food and Drug 
Safety had been listed as reimbursed medicines within the NHI with little consideration for budget 
impacts and/or cost-effectiveness [7]. 
 
Since the PLS implementation, 491 items were targeted for economic evaluation. 331 items (205 
substances), which accounted for 67.4% of the items, were approved on the basis of their cost 
effectiveness and were reimbursed as of December 31, 2013. 27.7% were not reimbursed, and the 
remaining 4.9% are still under assessment and awaiting decisions [1]. 
 
 
 
After HIRA¶VGHFLVLRQVUHJDUGLQJ reimbursements, medicines designated as potentially reimbursed 
require 60 days for face-to-face negotiation between the NHIS and the drug manufacturers in order to 
decide on their prices and the expected budget impact based on their anticipated utilization. During 
drug pricing negotiations, the NHIS considers the prices in OECD countries, Taiwan, Singapore, as 
well as the prices of substitute medicines in the same class or related class. In this process, the 
highest price that the NHIS can agree to is the price of medicines that the DREC has approved as 
cost-effective, and justifications for lowering drug prices are sought based on substitute drug prices or 
prices in countries outside of Korea. If the price negotiation fails, the medicine cannot be listed. Under 
these FLUFXPVWDQFHVWKHQHZPHGLFLQHPXVWJRWKURXJK+,5$¶VUHJLVWUDWLRQSURFHVVDJDLQ>@ 
 
Agreement on the expected volume of the new medicine is required for application at the agreed price 
in order to minimize the financial risk from introducing the new medicine. 
 
As a result, if the actual consumed volume of the new drug exceeds 30% of the expected volume 
after a year, the drug price must be renegotiated (Price Volume Agreements ± PVAs. Discussed in 
more detail below). PVAs are common among a number of European countries, especially where 
there are limited demand-side measures to regulate physician prescribing habits [9,10]. 
 
A total of 259 items were registered through drug price negotiations between 2007 and 2013. This 
constitutes 78.2% (259) of the 331 items that were approved for reimbursement by HIRA [1]. 
According to Kim et al., the average price negotiation was 86.9% (standard deviation 11.7%) of the 
agreed HIRA price. Consequently, drug price negotiations decreased the prices of new medicines by 
approximately 13.1% from the price approved for reimbursement by HIRA [11]. Consequently, can be 
considered successful. 
 
Pricing of generic medicines 
Generic medicines are currently priced at 53.55% of their originator price, i.e. a prescriptive pricing 
policy similar to countries such as France [12,13]. Equal medicine pricing (EMP) was implemented in 
$SULOXQGHUWKHQHZSULQFLSOHRIWKH³same medicine, same price [14]´LHLQWHUQDOUHIHUHQFH
pricing based on the molecule (ATC level 5) [15]. The previous pricing for generic medicines was 
established using a stepwise pricing scheme, i.e. the price was determined by the order of entrance 
into the market. Due to the EMP, the maximum price of generics has decreased to 53.55% from the 
previous 68% of the RULJLQDWRU¶s price. Kwon et al. (2015) recently researched whether the aim of the  
EMP to introduce market competition among outpatient drugs by setting the same price for both 
generics and the originator and expecting generic manufacturers to further lower their prices to attract 
greater sales was achieved. However, despite the expectation that active price competition between 
generics and originators would occur and lead to substantial utilization of lower-cost generics, the 
market share of the originator medicine remained high with no price competition in reality [3]. During 
2007±2013, a total of 10,071 generic products were listed, which amounts to an average annual 
listing of 1,439 generics per year [1]. This level of generic introduction is perhaps not surprising given 
potentially the high profitability for generics in Korea with prices of generics in a number of European 
countries as low as 2% to 10% of pre-patent loss originator prices [16-18]. 
 
Pricing of line extension medicines 
For line extension medicines, the price is set using the following equation, whose components include 
the substances and price of the registered drug as well as a new GUXJ¶V1FRQWHQW>@:  ܲܰ = ܣ ܺ ܤ, if N has higher dose, Eq(1) ܲܰ = ܣ» ܤ, if N has lower dose, Eq(2) 
where A is 53.55% of the price of the already listed drug, B = [(ܪ݄݅݃ ݀݋ݏ݁)/(ܮ݋ݓ ݀݋ݏ݁í 1]ܺ 0.5 + 1. 
 
For example, when simvastatin 20 mg has already been registered as costing $15, and if simvastatin 
10 mg(N) is to be newly registered, the calculated price becomes $10 ($15/B, B=1.5). 
 
Re-pricing measures 
Once listed, medicines can be subject to various and complicated re-pricing measures [19] as follows: 
 
Delisting 
Since 2007, listed medicines with no production and no claims history for two years are to be deleted 
from the reimbursement medicine list. Around 9,767 items were delisted during 2007±2013 [1]. 
 
Drug list re-arrangement 
With the implementation of the PLS in 2007, the need to re-arrange the medicines that were already 
listed was raised because these had not been listed based on their cost-effectiveness. Consequently, 
a drug list re-organization project was introduced in which drugs listed before 2007 would be re-
appraised based on their current cost-effectiveness. 
 
Registered drugs that were subsequently found not to be cost effective would be deleted from the 
reimbursement list. However, this project was contested by pharmaceutical companies, and contrary 
to its intention, the original plan was downgraded to a new method for drug price reduction in which 
the items were kept on the list if their prices were reduced over three years [20]. 
 
As a result, a reorganization of a total of 49 effective groups (12,825 items) was completed. Prices 
were reduced for 3,585 items, 546 items were delisted, and the costs saved on medicines 
expenditure was estimated at KRW 863.3 billion(USD 768 million) [21]. 
 
Price cuts due to kickbacks 
Kickbacks between prescribers and manufacturers have been illegal but prevalent in Korea [22]. In 
order to eradicate this, the Korean government legislated dual punishments in November 2010. This 
law intended to punish both the givers and takers of kickbacks. For manufacturers, the sales of 
corresponding items would be suspended or they would be fined, and the prices of their products 
would be cut by the amount of the kickbacks when kickbacks were detected. For prescribers, the 
punishment included a potential prison sentence for a maximum of two years, a fine of KRW 30 
million (USD 26,690) or less, and a suspension of their license without a fine for up to a year [23]. 
After 2011, there were kickbacks on 188 items and drug price reductions of up to 20% [21]. However, 
even after the legislation for drug price reduction was introduced, kickbacks continued to occur, and 
DVOLWLJDWLRQIRUDGPLQLVWUDWLYHVXVSHQVLRQRI02+:¶V regulations on drug price reductions came 
forward, questions were raised regarding the OHJLVODWLRQ¶VHIIHFWLYHQHVV&RQVHTXHQWO\IURP-XO\
2014, kickbacks were strongly regulated, and to make the measures on medicines caught in violation 
more effective, drugs in violation ceased to receive insurance reimbursements. If they were caught 
two times or more, they would be deleted from the reimbursement list, known as the two strikes out 
system [24]. This measure is proving more effective. 
 
Actual transaction pricing (ATP) 
The ATP aims to reduce the gap between the reimbursement price and the actual transaction price. 
Since the NHIS reimburses medicine costs based on reimbursement prices announced monthly, 
reimbursement prices are adjusted to actual prices by investigating the actual prices for medicines 
through auditing samples [19]. The average price reduction rate was 0.94% in 2010, estimated at 
KRW 15.4 billion(USD 13.7 million) in savings [1]. 
 
Price cut for originator medicines after patent expiration 
As mentioned, once a patent expires and generics enter the market, the price of the originator 
medicines will be lowered to 53.55% (internal reference pricing). This is due to the EMP policy 
introduced in April 2012. During the 12-month grace period before its application, the originator 
medicine was to cut its price by 30%, and, simultaneously, generics are to be priced at 85% of the 
RULJLQDWRU¶VSULFH(70% * 85% = 59.5%). After this period, the same molecules are to be priced at the 
same level, that is, 53.5% of the originDWRU¶VSULFH$pproximately 47% (6,506 products) of the total 
listed products were subject to price cuts [3]. The savings from these price cuts were estimated to be 
KRW 909 billion(USD 808.72 million) after six months of policy implementation [25]. 
 
Price-volume agreement (PVA) 
PVAs are typically agreed during price negotiations for new medicines. If the actual volume of claims 
exceeds 30% in the first year in relation to the annually expected volume, the drug becomes subject 
to a price reduction according to the PVA regulations. At this time, the drug manufacturer negotiates 
the price reduction gap with the NHIS, and the maximum gap is set at 10% [19]. After the negotiations 
were introduced in 2007, a total of 263 items went through price adjustments via the PVA. The 
average reduction was 6.6% [11]. 
 
Others 
There is a mechanism for mediation for either an increase or decrease in drug pricing as per requests 
from the manufacturer. Mediation mechanisms are often applied for requests for drug price increases, 
and there are also additional price increase requests on products deemed unfit for further production 
due to profitability reasons. Whether the drug price adjustment application is appropriate or not is 
DVVHVVHGE\+,5$¶s DREC, and the price increase for drugs that pass the assessment is 
subsequently determined by drug price negotiation with the NHIS [19]. Between 2007 and 2012, there 
were applications for mediation on 142 items, and the final price was determined as an average of 
78.9% of the price requested by the company [8]. 
 
Discussion 
)RU.RUHD¶VKHDOWKLQVXUDQFHV\VWHPWREHILQDQFLDOO\VXVWDinable, regulating drug pricing is important. 
This has been justified by the fact that the proportion of drug costs was high in relation to total medical 
costs. As such, there are various regulations on drug prices, and this study confirmed that, 
essentially, different regulations were applied depending on the type of the drug. These have worked 
reasonably well in lowering medicine prices as well as removing obsolete products from the 
reimbursement list. For new drugs, the listing and pricing scheme has been well established since the 
DERP in 2007. Specifically, a recent evaluation stated that value for money of new drugs has been 
well reflected in reimbursement decisions, and has contributed to improving transparency and 
rationality [7]. In contrast, drug price negotiations confirmed the need for improvements in 
transparency and consistency [11]. 
 
Generic drugs, which comprise 97.2% of annually listed drugs, are automatically priced via a simple 
standard [1,14]. Despite the large number of items, further price reductions through price competition 
does not appear to function properly in Korea [3]. In addition, re-pricing mechanisms are complicated 
and would appear redundant. After the PLS, a rearrangement of pre-listed medicines on the basis of 
cost-effectiveness was needed. Unfortunately, this was considered a regrettable policy failure 
because the listing initiative was transformed into various repricing mechanisms rather than assessing 
whether to continue to reimburse medicines based on their cost-effectiveness, as undertaken in for 
instance Sweden when they re-assessed the value of reimbursed products in designated classes [17], 
or not. Diverse and complicated measures for drug price reduction mechanisms can cause 
manufacturer dissatisfaction when planning longer term.  
 
To increase policy receptiveness, there is a need to strive for health insurance sustainability through 
effective drug price policieV$FFRUGLQJWRWKHJRYHUQPHQW¶s recent measures for drug price reforms, 
there is a tendency to weaken pharmaceutical price regulations under the policy of fostering 
pharmaceutical industry development [26]. In other words, policies for easing drug price regulations 
are being proposed under the assumption that drug price regulation leads to profit reduction for 
pharmaceutical companies, thereby discouraging the development of new innovative medicines, 
which will cause difficulty in maintaining global competitiveness.  
 
In the long run, there should be drug pricing policy management that involves follow-up of introduced 
policies before future policies are considered rather than implementing complex and inefficient pricing 
measures. This would reduce the dissatisfaction of pharmaceutical companies while maintaining the 
principle of value for money for new drugs and financial efficiency through price competition among 
generic drugs. Having said this, it is also acknowledged that gross profitability can be substantial for 
new medicines such as those for hepatitis C where companies where charging up to US$84,000 per 
course with cost of goods as low as US$100 ± 200 [27-29]. In addition, requested prices for new 
cancer medicines appear to currently bear little relation to research costs or to the health gain 
provided in terms of survival times [30], resulting in requests from clinicians to lower prices [31-33].  
 
To help fund new medicines, as well as greater use of existing medicines with ageing populations, 
whilst still maintaining population coverage close to 100%, there needs to be increasing use of  
generics at lower prices. Prices of generics in Europe can be as low as 2% to 10% of pre-patent loss 
prices through a variety of measures [15-18,34]. These include compulsory generic substitution, as 
well as encouraging high international non-proprietary name (INN) prescribing. In addition, regular 
review of generic prices and only funding the cheapest generics [15-18,34]. There appears 
considerable room for further price reductions of generic medicines in Korea, building on existing 
measures. These measures do not need to be complex. This along with initiatives to increase the 
prescribing of generics versus originators, as well as patented products in a class without 
compromising care, can achieve considerable savings in Korea.. In addition, re-focusing efforts on de-
listing or disinvestment of medicines no longer providing value. This builds on earlier measures in 
Korea before there was a re-focus on pricing as well as successful examples in other countries 
[35].These are considerations for the future. 
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